OptiNose
- Country
- 🇳🇴Norway
- Ownership
- Public
- Established
- 2000-01-01
- Employees
- 132
- Market Cap
- $155.3M
- Website
- http://www.optinose.com
- Introduction
OptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.
Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps
- Conditions
- Chronic Rhinosinusitis Without Nasal Polyps
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-02-27
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Optinose US Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT06850805
- Locations
- 🇺🇸
San Tan Allergy & Asthma, Gilbert, Arizona, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
🇺🇸DaVinci Research, LLC, Sacramento, California, United States
A Study to Evaluate Change in Viral Load After OPN-019 in Adults With COVID-19
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Optinose US Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT05035576
- Locations
- 🇲🇽
Fundacion Santos y de la Garza Evia, I.B.P, Monterrey, N.l., Mexico
Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Optinose US Inc.
- Target Recruit Count
- 223
- Registration Number
- NCT03960580
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Sacramento Ear, Nose & Throat Surgical and Medical Group Inc, Folsom, California, United States
🇺🇸BioSolutions Clinical Research Center, La Mesa, California, United States
Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps
- First Posted Date
- 2018-12-20
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Optinose US Inc.
- Target Recruit Count
- 332
- Registration Number
- NCT03781804
- Locations
- 🇺🇸
AZ Allergy & Immunology Research, Gilbert, Arizona, United States
🇺🇸Kern Research, Bakersfield, California, United States
🇺🇸Sacramento Ear, Nose & Throat Surgical and Medical Group Inc, Folsom, California, United States
OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps
- First Posted Date
- 2018-11-20
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Optinose US Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT03747458
- Locations
- 🇺🇸
Clinical Research Center of Alabama, Birmingham, Alabama, United States
🇺🇸Arizona Allergy and Immunology Research, Gilbert, Arizona, United States
🇺🇸San Tan Allergy & Asthma, Gilbert, Arizona, United States
Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video
- First Posted Date
- 2018-07-18
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Optinose US Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT03591068
- Locations
- 🇺🇸
University of Colorado SOM, Department of Otolaryngology, Aurora, Colorado, United States
🇺🇸University of Texas Health Science Center at Houston, McGovern Medical School, Dept. of Otolaryngology, Head and Neck Surgery, Houston, Texas, United States
A Study to Compare the Bioavailability Intranasal Administration of 200 and 400 µg or 400 µg Alone of OPTINOSE™ FLUTICASONE With 440 µg of Flovent® HFA (Fluticasone Propionate) Inhalation Aerosol (Part 2)
- Conditions
- Mild to Moderate Asthma
- Interventions
- Drug: OPTINOSE™ FLUTICASONE
- First Posted Date
- 2014-10-17
- Last Posted Date
- 2016-02-03
- Lead Sponsor
- Optinose US Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT02266927
- Locations
- 🇮🇪
Celerion, Belfast, Ireland
Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device
- First Posted Date
- 2012-06-21
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Optinose US Inc.
- Target Recruit Count
- 323
- Registration Number
- NCT01624662
- Locations
- 🇺🇸
Bensch Clinical Research LLC, Stockton, California, United States
🇺🇸Colorado Allergy & Asthma Centers, PC, Centennial, Colorado, United States
🇺🇸Advanced ENT and Allergy, Louisville, Kentucky, United States
Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety
- First Posted Date
- 2012-06-19
- Last Posted Date
- 2018-12-26
- Lead Sponsor
- Optinose US Inc.
- Target Recruit Count
- 323
- Registration Number
- NCT01622569
- Locations
- 🇺🇸
SC Clinical Research, Inc., Tucson, Arizona, United States
🇺🇸Kern Allergy and Medical Research, Inc., Bakersfield, California, United States
🇺🇸Central California Clinical Research, Fresno, California, United States
Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps
- Conditions
- Chronic Sinusitis With or Without Nasal Polyps
- Interventions
- First Posted Date
- 2012-06-19
- Last Posted Date
- 2016-08-29
- Lead Sponsor
- Optinose US Inc.
- Target Recruit Count
- 705
- Registration Number
- NCT01623323
- Locations
- 🇺🇸
Precision Trials, Phoenix, Arizona, United States
🇺🇸Colorado ENT and Allergy, Colorado Springs, Colorado, United States
🇺🇸Sher Allergy, Largo, Florida, United States